Friday, July 31, 2026

Daewoong Pharmaceutical holds “Nabota Master Class,” demonstrates proprietary procedures

Daewoong Pharmaceutical hosted the "Nabota Master Class" for 74 medical professionals from 13 countries, focusing on safety and clinical application.

North Korea-Russia Alliance: What’s Next After 2 Years of Strategic Partnership?

North Korea emphasizes strengthening ties with Russia on the treaty's anniversary, highlighting political, economic, and cultural cooperation.

U.S. Allies Ramp Up Pressure with Fresh Sanctions on North Korea and Russia

The government has designated seven North Korean...

Tag: biopharmaceuticals

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Samsung Bioepis Launches AI Academy: How 1,000 Employees Will Master AI by July 2026

Samsung Bioepis launches an AI training program for employees to enhance skills in biopharmaceuticals, boosting global competitiveness.

How SK Life Science is Bridging Communication Gaps in Epilepsy Management

SK Life Science will present findings on epilepsy treatment and patient-provider communication at the 2026 AAN Annual Meeting in Chicago.

Pangen Expands Cell-Based Bioassay Services for Customized Drug Development

Pangen is expanding its cell-based activity analysis services after a new contract, enhancing drug evaluation capabilities for various medications.

Samsung Biologics Wins “Sustainability Leadership” at CDMO Awards: What This Means for the Future of Biopharma

Samsung Biologics wins the Sustainability Leadership award, marking a 13-year streak and highlighting its commitment to sustainable practices.

Samsung Biologics America Achieves Record Profit: What This Means for Global Expansion in 2026

Samsung Biologics America reports record profits, showcasing its successful global expansion strategy despite previous revenue dips.

Lotte Biologics Wins CDMO Leadership Award… Validates “Quality Management”

Lotte Biologics wins "Best New or Relaunched CDMO" at the 2026 CDMO Leadership Awards, showcasing rapid growth and global recognition.

Alteogen and Biogen: A Game-Changing 200 Million USD License Deal for ALT-B4 Biopharmaceuticals

Alteogen partners with Biogen for exclusive licensing of subcutaneous biopharmaceuticals, potentially earning up to 549 million USD.

Samsung Biologics Strengthens Global Partnerships at Decat Week 2026: Key Insights and Strategies

Samsung Biologics aims to enhance global partnerships at J.P. Morgan's Healthcare Conference 2026, showcasing its CDMO strengths.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Dongkoo Bio&Pharma Invests 1 Billion KRW in GenomAndCompany: What This Means for ADC Drug Development

Dongkoo Bio&Pharma invests 1 billion KRW in Genome & Company to enhance antibody and ADC drug development strategies.

Celltrion’s Strategic Move: How Local Production in the U.S. Can Mitigate Tariff Risks

Celltrion outlines its Branchburg facility's operations and plans to mitigate tariff risks by establishing local production and a supply system.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

How ABL Bio’s Grabody-B Revolutionizes siRNA Delivery: A Game-Changer for Brain Disease Treatment?

ABL Bio's Grabody-B technology effectively delivers siRNA across the blood-brain barrier, enhancing treatment for brain and systemic diseases.

GC Biopharma Corp Soars After Eight Years on the Back of Immunodeficiency Drug Alyglo, Posting Results in U.S. Market Push

GC Biopharma Corp breaks its fourth-quarter deficit with ALYGLO's success, achieving $106M in annual revenue and plans for future growth.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.